Login to Your Account

Biodel Shares Take Big Hit on Diabetes Data Unknowns

By Catherine Hollingsworth

Tuesday, September 9, 2008
Biodel Inc. said that two Phase III trials of diabetes treatment VIAject met the studies' objective of noninferiority to Eli Lilly and Co.'s Humulin insulin injection, but Wall Street seemed leery of the results because data from India were excluded. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription